Naturally occurring deamidated triosephosphate isomerase is a promising target for cell-selective therapy in cancer.

ABSTRACT: Human triosephosphate isomerase (HsTIM) is a central glycolytic enzyme and is overexpressed in cancer cells with accelerated glycolysis. Triple-negative breast cancer is highly dependent on glycolysis and is typically treated with a combination of surgery, radiation therapy, and chemotherapy. Deamidated HsTIM was recently proposed as a druggable target. Although thiol-reactive drugs affect cell growth in deamidated HsTIM-complemented cells, the role of this protein as a selective target has not been demonstrated. To delve into the usefulness of deamidated HsTIM as a selective target, we assessed its natural accumulation in breast cancer cells. We found that deamidated HsTIM accumulates in breast cancer cells but not in noncancerous cells. The cancer cells are selectively programmed to unde

SUBMITTER: Enriquez-Flores S 

PROVIDER: S-EPMC8901631 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature